Abstract
551 Objective: We analyzed retrospectively the incidence and tumor characteristics of CBC, and determine prognostic factors of their occurrence, and contribution of adjuvant treatments. Methods: Among the 8 FASG trials, 3,653 pts were assessable: 1,667 received adjuvant chemotherapy (CT), 936 CT plus tamoxifen (Tam), 682 hormonotherapy alone, and 368 no systemic treatment. In 2,603 pts receiving CT, it was FEC regimens (epirubicin [E] 50,75, or 100 mg/m2) in 85%, and other E-based CT in the others. The median follow-up was 9 years. The event-free survival (EFS) was computed in a multivariate model: the first step determined separately prognostic factors and adjuvant treatment effects, the second step combined both. Results: 152 pts (4.2%) developed a CBC with a 9-year EFS of 94.9%. The median time to develop a CBC was 52 months: the onset periods were mainly during the second and the seventh years after the primary diagnosis. The comparison with primary tumor showed that CBC presented with the same histology in 56% of cases, and with the same hormone receptors status in 36%. On the whole population, the multivariate analysis showed that independent prognostic factors of CBC occurrence were: negative progesterone-receptor (PR-) with a relative risk (RR) of 2.92 (P < 10-3) and premenopausal status (RR = 1.56, P = .03). As regards treatment effects, the multivariate analysis showed a favorable role of hormonal treatment (P = .04), whereas CT, number of CT cycles, and E dose-intensity had no significant effect. When prognostic factors and treatment effects were combined in the model, the only independent prognostic factor to develop a CBC was PR- with RR = 2.61 (P < 10-3). Conclusion: The incidence of CBC observed in our EBC adjuvant trials was classical of those previously described in the literature. Of interest, when we combined baseline prognostic factors and treatment modalities, the only independent factor of CBC was PR status. Probably, PR negative pts must be carefully monitor, increasing the frequency of contralateral mammography during their follow-up. No significant financial relationships to disclose.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
